The Life Sciences team advised Poplar Therapeutics, Inc. on the closing of its Series A extension round, bringing its total Series A financing to $95 million. The round was led by Janus Henderson Investors with RA Capital also participating as a new investor. The financing was further supported by existing investors, including SR One, Vida Ventures, and affiliates of ArrowMark Partners. The additional capital from this financing will support the continued advancement of its lead asset, PHB-050, through clinical development.
Poplar Therapeutics, Inc. is a clinical-stage immunology company developing a new class of anti-IgE therapy to challenge convention in treating allergic disorders, which was incorporated in 2024. Its lead program, PHB-050, is a next-generation anti-IgE antibody with a unique triple-action design currently being studied in atopic diseases. Poplar is pursuing the bold idea that IgE can be rapidly driven toward zero, with the goal of helping people with IgE-mediated conditions move from fear toward freedom.
The Goodwin team was led by Kevin Kabler and Zach Newman.
For more information on the deal, please read the press release.